Copyright ©2014 Baishideng Publishing Group Inc.
World J Hepatol. May 27, 2014; 6(5): 315-325
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.315
Table 1 Recommendations for the management of hepatitis B and C infection before and after liver or renal transplantation
Chronic hepatitis BChronic hepatitis C
Liver transplantationKidney transplantationLiver transplantationKidney transplantation
Pre transplantNAs1Peg IFN ± RBV ± DAAs3 (depending on genotype and type of DAA)PegIFN plus very low dose RBV (plus DAAs)4
Post transplantProphylaxis and treatmentNo prophylaxis2
Short term HBIG plus NANAs1Peg IFN ± RBV ± DAAs3 (depending on genotype and type of DAA)Peg IFN plus very low dose RBV
Table 2 Safety and efficacy of the combined regimen, interferon, ribavirin and protease inhibitors to treat hepatitis C after liver transplantation
Boceprevir (n)Telaprevir (n)Complete virological responseSide effects
Coilly et al[72]181958% TVRAnemia 92%
89% BOCInfections 27%
Fatal events 8%
Pungpapong et al[73]313586% TVRAnemia 95%
48%BOCInfections 10%
Renal dysfunction 76%
Fatal events 3%
Werner et al[74]-988.80%Anemia 75%
Rash 33%
Renal dysfunction 33%
Stravitz et al[75]5062%Anemia 82%
Renal failure
Fatal events 7%
Ann Brown et al[76]-4660%Anemia 48%
Rash 35%
Pruritus 22%
Renal failure 22%
Infections 22%
Anorectal symptoms 41%
Forns et al[77]Sofosbuvir 11578%Fatal events 16%
Table 3 Prophylactic schemes against hepatitis B virus recurrence after liver and renal transplantation when grafts are from hepatitis B virus positive donors
Liver transplantationAnti-HBc positiveHBsAg positiveHBIG plus NA
HBsAg negativeNo prophylaxis
Anti-HBc positive
Anti-HBs positive
Anti-HBc negativeLong term lamivudine
Anti-HBs negative
HBsAg positiveAnti-HBc positiveHBIG plus NA
Kidney transplantationAnti-HBc positiveHBsAg negativeNo prophylaxis
Treatment when HBV DNA increases
HBsAg positiveHBsAg positiveHBIG plus lamivudine
(HBV DNA negative)HBsAg negativeLong term lamivudine
(HBV DNA) negative